Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 59

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 59
---
 (including benefits) for such services under applicable plans and arrangements which may be funded with proceeds from the PIPE Financing.

Aadi’s board of directors was aware of and considered those interests, among other matters, in reaching its decision to approve the PIPE Financing and
related matters, including the Subscription Agreement, Registration Rights Agreement and form of Pre-Funded Warrant, and recommend the approval of the PIPE Financing and related matters to Aadi stockholders.
These interests, among other factors, may have influenced the directors and executive officers of Aadi to support or approve the PIPE Financing.

For
more information regarding the interests of Aadi’s directors, executive officers and principal stockholders in the PIPE Financing, please see the sections titled “The PIPE Financing and License Agreement—Interests of Aadi’s Directors and Executive Officers in the PIPE Financing” beginning on page 112.

Risks Related to the License Agreement and the ADC Programs

Following the Divestment, we will not have any approved products and our pipeline will comprise solely of preclinical assets. The ADC Programs are early in development. Going forward, our business will depend on our ability to advance our current and future product candidates through preclinical studies and clinical trials and obtain regulatory approval of our product candidates, which may fail in development or suffer delays that adversely affect their commercial viability.

Following the
Divestment, we will not have any approved products and our pipeline will comprise solely of preclinical assets. Going forward, our business and future operating results will be dependent on our ability to successfully advance, develop and obtain
regulatory approval for and/or commercialize our current and future product candidates and discover or in-license additional preclinical or clinical assets. Our ability to generate product or other revenue, which we do not expect will occur for many
years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates, which may never occur.

Prior
to initiating clinical trials of our product candidates, we will need to initiate or complete IND-enabling studies for each of our ADC Programs and we will need to file an IND or similar application to the FDA or regulatory authorities in other
jurisdictions. We expect to submit an IND with respect to our lead product candidate PTK7-CPT113 in the second half of 2025 but we may not be able to file the INDs for our product candidates on the timelines we expect. For example, we may experience
manufacturing delays or other delays with IND-enabling studies. Moreover, we cannot be sure that submission